You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 129 No. 8, August 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Oncology
 •Head & Neck Cancer
 •Dentistry/ Oral Medicine
 •Neoplasms of Head & Neck
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic

Topical Chemoprevention of Oral Cancer With Tretinoin "Biofilm"

Zhi Wang, MD; Raju Polavaram, MD; Cesar F. Fuentes, MD; Stanley M. Shapshay, MD

Arch Otolaryngol Head Neck Surg. 2003;129:869-873.

Background  Oral cancer is a common malignancy. Chemoprevention is a promising treatment strategy but it produces systemic toxic effects. Topical application of chemopreventive agents is an attractive alternative that reduces toxic effects. This study is based on the hypothesis that topical application of mucosal adhesive film (MAF), as a means to deliver tretinoin, is effective and safe for oral cancer chemoprevention.

Setting  Randomized animal study conducted at the Boston University School of Medicine.

Design  This study uses the hamster cheek-pouch model to test efficacy and safety of the MAF/tretinoin patch for oral cancer prevention. The oral mucosa of 36 hamsters was painted with dimethylbenzanthracene to produce premalignant lesions. The 36 hamsters were divided into 3 groups of 12 hamsters each as follows: (1) control, no treatment; (2) systemic tretinoin (5.0 mg/kg per day, intraperitoneally); and (3) topically applied MAF/tretinoin patch (0.45 mg tretinoin/cm2, once daily). Treatments continued for 40 days.

Main Outcome Measures  Tumor growth and burden were measured over time. The duration of MAF patch retention on mucosa and local tissue reaction to the treatment were also evaluated.

Results  The patch stayed on the mucosa for at least 5 hours with no evidence of inflammatory or other adverse reactions from the treated tissue. There was a significant difference in the tumor growth measurement between the control and systemic tretinoin groups (P<.001), and between the control and MAF patch groups (P<.001).

Conclusions  This is the first study, to our knowledge, to use a polymer MAF technique for oral cancer prevention. The MAF/tretinoin patch is safe and effective for such chemoprevention in the hamster model.


From the Department of Otolaryngology–Head and Neck Surgery, Boston Medical Center/Boston University School of Medicine, Boston, Mass. The authors have no relevant financial interest in this article.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hamster check pouch--not a mucosal surface!
Vet Pathol 2007;44:963-964.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.